The MTOPS Study: New Findings, New Insights, and Clinical Implications for the Management of BPH

European Urology, Supplements

Volumn 5, Issue 9, 2006, Pages 628-633

  Marberger, Michael ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Benign prostatic hyperplasia; Combination therapy; Doxazosin; Finasteride; Medical Therapy of Prostatic Symptoms (MTOPS)

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; DOXAZOSIN; DUTASTERIDE; FINASTERIDE; PLACEBO; PROSTATE SPECIFIC ANTIGEN; STEROID 5ALPHA REDUCTASE INHIBITOR; TAMSULOSIN; TERAZOSIN;

ARTICLE; ASTHENIA; CLINICAL TRIAL; DISEASE COURSE; DIZZINESS; DRUG HYPERSENSITIVITY; DYSPNEA; EJACULATION DISORDER; ERECTILE DYSFUNCTION; FOLLOW UP; HUMAN; INVASIVE PROCEDURE; LIBIDO DISORDER; MONOTHERAPY; ORTHOSTATIC HYPOTENSION; PERIPHERAL EDEMA; PRIORITY JOURNAL; PROGNOSIS; PROSTATE; PROSTATE HYPERTROPHY; RISK REDUCTION; SOMNOLENCE; URINE RETENTION;

EID: 33744792615     PISSN: 15699056     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eursup.2006.05.002     Document Type: Article

References (27)

1. Berry S.J., Coffey D.S., Walsh P.C., et al. The development of human benign prostatic hyperplasia with age. J Urol 132 (1984) 474-479
2. Girman C.J., Jacobsen S.J., Tsukamotot T., et al. Health-related quality of life associated with lower urinary tract symptoms in four countries. Urology 51 (1998) 428-436
3. Jacobsen S.J., Girman C.J., Guess H.A., Rhodes T., Oesterling J.E., and Lieber M.M. Natural history of prostatism: longitudinal changes in voiding symptoms in community dwelling men. J Urol 155 (1996) 595-600
4. Roberts R.O., Jacobsen S.J., Jacobsen D.J., Rhodes T., Girman C.J., and Lieber M.M. Longitudinal changes in peak urinary flow rates in a community-based cohort. J Urol 163 (2000) 107-113
5. Jacobsen S.J., Jacobsen D.J., Girman C.J., et al. Natural history of prostatism: risk factors for acute urinary retention. J Urol 158 (1997) 481-487
6. Emberton M., Andriole G.L., de la Rosette J., et al. Benign prostatic hyperplasia: a progressive disease of aging men. Urology 61 (2003) 267-273
7. McConnell J.D., Roehrborn C.G., Bautista O.M., et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 349 (2003) 2387-2398
8. Madersbacher S., Alivizatos G., Nordling J., Sanz C.R., Emberton M., and de la Rosette J.J. EAU 2004 guidelines on assessment, therapy and follow-up of men with lower urinary tract symptoms suggestive of benign prostatic obstruction (BPH guidelines). Eur Urol 46 (2004) 547-554
9. AUA Practice Guidelines Committee. AUA guidelines on management of benign prostatic hyperplasia (2003). Chapter 1. Diagnosis and treatment recommendations. J Urol 170 (2003) 530-547
10. Marberger M.J. Long-term effects of finasteride in patients with benign prostatic hyperplasia: a double-blind, placebo-controlled, multicenter study. PROWESS Study Group. Urology 51 (1998) 677-686
11. McConnell J.D., Bruskewitz R., Walsh P., et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. N Engl J Med 338 (1998) 557-563
12. Lepor H., Auerbach S., Puras-Baez A., et al. A randomized, placebo-controlled multicenter study of the efficacy and safety of terazosin in the treatment of benign prostatic hyperplasia. J Urol 148 (1992) 1467-1474
13. Roehrborn C.G. Efficacy and safety of once-daily alfuzosin in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a randomized, placebo-controlled trial. Urology 58 (2001) 953-959
14. Boyle P., Roehrborn C., Harkaway R., Logie J., de la Rosette J., and Emberton M. 5-Alpha reductase inhibition provides superior benefits to alpha blockade by preventing AUR and BPH-related surgery. Eur Urol 45 (2004) 620-626
15. Imperato-McGinley J., Gautier T., Zirinsky K., et al. Prostate visualization studies in males homozygous and heterozygous for 5 alpha-reductase deficiency. J Clin Endocrinol Metab 75 (1992) 1022-1026
16. Debruyne F., Barkin J., van Erps P., et al. Efficacy and safety of long-term treatment with the dual 5 alpha-reductase inhibitor dutasteride in men with symptomatic benign prostatic hyperplasia. Eur Urol 46 (2004) 488-494
17. Lepor H., Williford W.O., Barry M.J., et al. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. N Engl J Med 335 (1996) 533-539
18. Kirby R.S., Roehrborn C., Boyle P., et al. The efficacy and tolerability of doxazosin and finasteride, alone or in combination, in the treatment of symptomatic benign prostatic hyperplasia: the Prospective European Doxazosin and Combination Therapy (PREDICT) trial. Urology 61 (2003) 119-126
19. Rhodes T., Girman C.J., Jacobsen D.J., Roberts R.O., Lieber M.M., and Jacobsen S.J. Longitudinal prostate volume in a community-based sample: 7 year follow up in the Olmsted County Study of urinary symptoms and health status among men. J Urol 163 (2000) 249 (abstract no. 1105)
20. Jacobsen S.J., Jacobson D.J., Girman C.J., et al. Treatment for benign prostatic hyperplasia among community dwelling men: the Olmsted County study of urinary symptoms and health status. J Urol 162 (1999) 1301-1306
21. Arrighi H.M., Metter E.J., Guess H.A., and Fozzard J.L. Natural history of benign prostatic hyperplasia and risk of prostatectomy. The Baltimore Longitudinal Study of Aging. Urology 38 (1991) 4-8
22. Roehrborn C.G., McConnell J.D., Lieber M., et al. Serum prostate-specific antigen concentration is a powerful predictor of acute urinary retention and need for surgery in men with clinical benign prostatic hyperplasia. PLESS Study Group. Urology 53 (1999) 473-480
23. Roehrborn C.G. The potential of serum prostate-specific antigen as a predictor of clinical response in patients with lower urinary tract symptoms and benign prostatic hyperplasia. BJU Int 93 (2004) 21-26
24. Crawford E.D., Wilson S.S., McConnell J.D., et al. Baseline factors as predictors of clinical progression of benign prostatic hyperplasia in men treated with placebo. J Urol 175 (2006) 1422-1427
25. Kaplan S.A., McConnell J.D., Roehrborn C.G., et al. Combination therapy with doxazosin and finasteride for benign prostatic hyperplasia in patients with lower urinary tract symptoms and a baseline total prostate volume of 25 ml or greater. J Urol 175 (2006) 217-221
26. Barkin J., Guimaraes M., Jacobi G., Pushkar D., Taylor S., and van Vierssen Trip O.B. Alpha-blocker therapy can be withdrawn in the majority of men following initial combination therapy with the dual 5alpha-reductase inhibitor dutasteride. Eur Urol 44 (2003) 461-466
27. Baldwin K.C., Ginsberg P.C., Roehrborn C.G., and Harkaway R.C. Discontinuation of alpha-blockade after initial treatment with finasteride and doxazosin in men with lower urinary tract symptoms and clinical evidence of benign prostatic hyperplasia. Urology 58 (2001) 203-209